VON ESCHENBACH WINS SENATE APPROVAL

JANUARY 01, 2007

Despite 9 months of holdups by Congress, the Senate approved the nomination of Acting FDA Commissioner Andrew von Eschenbach, MD, to permanently head the agency. He has served as interim head of the FDA since September 2005.

Republican Sens Charles E. Grassley (Iowa) and David Vitter (La) had placed holds on the nomination. Retiring Majority Leader Bill Frist (R, Tenn), however, forced a procedural vote that allowed the Senate to vote on the nomination despite the holds. During President Bush's term, the FDA has been without a permanent commissioner for all but 18 months.

The next year could prove challenging for the agency. With the Democrats controlling Congress, many have criticized the FDA on its monitoring of the safety of drugs. Furthermore, the law that permits the agency to collect fees from companies to accelerate the new drug approval process expires in 2007. The Democrats will most likely use the reauthorization of the legislation as a means to push for changes at the agency.




SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.